Skip to main content
Back
Watch Compare

PDS Biotechnology Corp

Data quality: 83%
PDSB
Nasdaq Manufacturing Chemicals
$1.08
▲ $0.01 (0.93%)
Mkt Cap: 60.56 M
Price
$1.09
Mkt Cap
60.56 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Negative free cash flow of -27.75 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-271.48%
Below sector avg (-53.34%)
ROIC-99.04%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio2.09
Interest Coverage-5.91

Valuation

PE (TTM)
-1.76
Below sector avg (-1.47)
P/B Ratio6.41
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -1.8 -1.5
P/B 6.4 1.6
ROE % -271.5 -53.3
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -34.50 M
ROE -271.48% ROA -91.77%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -27.75 M
ROIC -99.04% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2.09
Interest Coverage -5.91 Asset Turnover N/A
Working Capital 14.56 M Tangible Book Value 9.45 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.76 Forward P/E N/A
P/B Ratio 6.41 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -45.83%
Market Cap 60.56 M Enterprise Value 34.36 M
Per Share
EPS (Diluted TTM) -0.74 Revenue / Share N/A
FCF / Share -0.50 OCF / Share -0.50
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 80.45%
SBC-Adj. FCF -32.48 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -34.50 M -37.61 M -42.94 M -40.85 M -16.92 M
EPS (Diluted) -0.74 -1.03 -1.39 -1.43 -0.66
Gross Profit — — — — —
Operating Income -31.54 M -36.32 M -43.05 M -41.67 M -21.44 M
EBITDA — — — — —
R&D Expenses 19.03 M 22.57 M 27.76 M 29.43 M 11.25 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 5.34 M 4.66 M 4.21 M 1.32 M —
Income Tax -1.17 M -869,169.0 -1.41 M -1.20 M -4.52 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 30.49 M 45.36 M 59.39 M 77.01 M 67.20 M
Total Liabilities 21.24 M 26.35 M 33.26 M 33.01 M 3.99 M
Shareholders' Equity 9.25 M 19.00 M 26.13 M 44.00 M 63.21 M
Total Debt — — — — —
Cash & Equivalents 26.71 M 41.69 M 56.56 M 73.82 M 65.24 M
Current Assets 28.25 M 45.05 M 59.06 M 76.48 M 66.84 M
Current Liabilities 9.48 M 17.09 M 13.63 M 9.82 M 3.76 M